Launch Of Virbac's Canigen Lepto4 Vaccine Aims To Offer Practices Choice
10 years ago 
1566 views
Virbac has launched the Canigen Lepto4® vaccine to give practices both choice and flexibility to better meet the needs of their clients. Canigen Lepto4 is offered alongside Canigen Lepto2® and covers two additional strains of Leptospirosis, recently identified as being of concern in certain high-risk groups in the UK and in dogs which may be travelling abroad.
Both vaccines are offered, along with the comprehensive Canigen range, with full technical training and support from Virbac to allow practices to choose their vaccine protocols based on the needs of their clients. This includes a suite of educational and promotional resources to enable practices to engage with their clients and help to make informed decisions about Leptospirosis vaccination for their dog.
Commenting on the introduction of Canigen Lepto4, Sarah Walker MRCVS, Product Manager, said: "We are committed both to providing our practices with a full and flexible range of canine vaccines and to offering them all the support they need to advise their clients effectively on this important issue.
"While Canigen Lepto2 is still perfectly suitable in many cases and provides a broad spectrum of protection, the launch of Canigen Lepto4 helps to offer a solution for those who may needed a broader degree of protection through being at a higher risk or those which travel abroad."
Founded by a veterinary surgeon, Virbac is dedicated to supporting the veterinary profession, the trade and farmers through the development of innovative products and services. One of the largest independent veterinary pharmaceutical companies in the world, its wide product portfolio includes many market-leading and award-winning products for large and small animals. Virbac works in close partnership with its customers, providing the advice and support they need to run successful, profitable businesses.
For further information:
Rebecca George
George PR
Tel: 01449 737281
Mob: 07974 161108
Email: [email protected]
More from Virbac Animal Health
- Virbac announces the arrival of Canixin® L, a new L2 Leptospirosis vaccine for dogs
- Virbac Strengthens Feline Portfolio with Acquisition of Thyronorm® for Feline Hyperthyroidism
- Virbac Announces Complimentary CPD Webinar: Introducing Vikaly™ – A New Era in Feline CKD Management
- Virbac Launches Vikaly™: The World’s First 2-in-1 Medicated Food for Cats
- Virbac Champions Excellence at the 2025 Cream Awards in the Dairy Vet Categories
